Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.44 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.44 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.44 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9704461 | 0.86 | LMNA (0.43) | ALDH1A1POLBLMNAGRIN2DGRIN3B | |
| SCHEMBL11349805 | 0.86 | LMNA (0.43) | ALDH1A1POLBLMNAGRIN2DGRIN3B | |
| SCHEMBL9703575 | 0.86 | GRIN2D (0.63) | LMNAGRIN2DGRIN3BGRIK1GRIA1 | |
| SCHEMBL9705717 | 0.86 | SIRT2 (0.44) | ALDH1A1SMN1; SMN2POLBLMNAGRIN2D | |
| SCHEMBL6602465 | 0.85 | CHEK1 (0.53) | — | |
| SCHEMBL9703959 | 0.85 | KMT2A (0.54) | ALDH1A1SMN1; SMN2POLBLMNAMAPT | |
| SCHEMBL6377630 | 0.83 | ALDH1A1 (0.51) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2POLB | |
| SCHEMBL6375213 | 0.83 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP2C19SMN1; SMN2POLB | |
| SCHEMBL11258206 | 0.82 | GRIN2D (0.51) | LMNAGRIN2DGRIN3BGRIK1GRIA1 | |
| SCHEMBL9704323 | 0.82 | GAA (0.53) | ALDH1A1SMN1; SMN2POLBLMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224954-A1 | Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds | GRUNENTHAL GMBH (DE) | 2004-11-11 | — | — | US | disclosed |
| US-5663179-A | CAN SENSITIZE MULTIDRUG RESISTANT CANCER CELLS TO CHEMOTHERAPEUTIC AGENTS | LABORATOIRES GLAXO SA (FR) | 1997-09-02 | — | — | US | disclosed |
| EP-0649410-B1 | ANILIDE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0649410-A1 | ANILIDE DERIVATIVES. | GLAXO LAB SA (FR) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994001408-A1 | ANILIDE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1994-01-20 | — | — | WO | disclosed |
| WO-1992011245-A1 | 2-ACYLAMIDO DERIVATIVES OF 3,4-DIHYDRO-3-OXO-QUINOXALINE HAVING PHARMACEUTICAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 1992-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224954-A1 | Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds | NQO2, NQO1, CYP2C8 | ALDH1A1 882/4885CYP1A2 22/4885CYP2C19 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.